CCL-34, a synthetic bioactive glycolipid developed previously from our research team, has been reported as a TLR4 activator, promoting macrophage activation and macrophage-mediated cytotoxicity of cancer cells [11], [12]. This evidence concerns the gene TLR4 and cancer.